Skip to main content
Premium Trial:

Request an Annual Quote

Amphora Raises $20M in Series C Private-financing Round

NEW YORK, Dec. 8 (GenomeWeb News) - Amphora Discovery has raised $20 million in a Series C round of private financing led by venture capital firm the 3i Group, the company said today.

New investors in the firm included Novartis Venture Fund and Aventis Capital, the venture arms of Novartis and Sanofi-Aventis, respectively. Previous investors Arch Venture Partners, MPM Capital, Venrock Associates, and Versant Ventures also participated in the recent round of financing.

Research Triangle Park, NC-based Amphora has developed a platform for drug discovery that integrates its own compound purification, characterization, and quantification technology, microplate processing system, and Caliper Technologies' microfluidics.

Amphora offers drug firms target-based discovery and pathway profiling services based on the technology. The firm also is developing a pipeline of small-molecule therapeutics, which are currently in preclinical development.

Two years ago, Amphora raised $23 million in a Series B round of venture funding.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.